

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Regorafenib for previously treated or metastatic
gastrointestinal stromal tumours**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes. Potential equality issues around the use of regorafenib earlier in the course of the disease in people with wild-type disease and resistant mutations, for whom imatinib is ineffective were raised during the draft scope consultation.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The potential issues raised were not considered to be equality issues that need to be addressed by the Committee because regorafenib can only be appraised within its marketing authorisation for people with unresectable or metastatic gastrointestinal stromal tumours whose disease has progressed on, or who are intolerant to, previous treatment with imatinib and sunitinib.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made to the draft scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to potential equality issues were identified.

Approved by Associate Director (name): Helen Knight

Date: 16/01/2017